Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Pinato

Showing results (131-140 of 238) with videos related to

Pageof 24
Sort By:
The Lancet. Oncology|October 22, 2024
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysisAntonio D'Alessio, Bernardo Stefanini, Julia Blanter, et al.
Journal for Immunotherapy of Cancer|June 16, 2022
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched studyBrett Marinelli, Edward Kim, Antonio D'Alessio, et al.
Cancers|October 28, 2023
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and SurvivalKhalil Choucair, Caroline Nebhan, Alessio Cortellini, et al.
Therapeutic Advances in Medical Oncology|May 17, 2021
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinomaTomi Jun, Umut Ozbek, Sirish Dharmapuri, et al.
Cancers|July 16, 2020
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI GradeDavid J Pinato, Takahiro Kaneko, Anwaar Saeed, et al.
Frontiers in Oncology|March 3, 2023
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitorsY Linda Wu, Grace van Hyfte, Umut Özbek, et al.
Chemotherapy|April 28, 2024
The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour BurdenJames Alexander Korolewicz, Bernhard Scheiner, Claudia A M Fulgenzi, et al.
Journal for Immunotherapy of Cancer|September 2, 2020
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international studyPetros Fessas, Ahmed Kaseb, Yinghong Wang, et al.
Journal for Immunotherapy of Cancer|September 14, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinomaTim F Greten, Ghassan K Abou-Alfa, Ann-Lii Cheng, et al.
JHEP Reports : Innovation in Hepatology|June 5, 2023
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinomaDavid J Pinato, Takahiro Kaneko, Antonio D'Alessio, et al.
Pageof 24

Showing results (131-140 of 238) with videos related to

Sort By:
Pageof 24
The Lancet. Oncology|October 22, 2024
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysisAntonio D'Alessio, Bernardo Stefanini, Julia Blanter, et al.
Journal for Immunotherapy of Cancer|June 16, 2022
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched studyBrett Marinelli, Edward Kim, Antonio D'Alessio, et al.
Cancers|October 28, 2023
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and SurvivalKhalil Choucair, Caroline Nebhan, Alessio Cortellini, et al.
Therapeutic Advances in Medical Oncology|May 17, 2021
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinomaTomi Jun, Umut Ozbek, Sirish Dharmapuri, et al.
Cancers|July 16, 2020
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI GradeDavid J Pinato, Takahiro Kaneko, Anwaar Saeed, et al.
Frontiers in Oncology|March 3, 2023
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitorsY Linda Wu, Grace van Hyfte, Umut Özbek, et al.
Chemotherapy|April 28, 2024
The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour BurdenJames Alexander Korolewicz, Bernhard Scheiner, Claudia A M Fulgenzi, et al.
Journal for Immunotherapy of Cancer|September 2, 2020
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international studyPetros Fessas, Ahmed Kaseb, Yinghong Wang, et al.
Journal for Immunotherapy of Cancer|September 14, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinomaTim F Greten, Ghassan K Abou-Alfa, Ann-Lii Cheng, et al.
JHEP Reports : Innovation in Hepatology|June 5, 2023
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinomaDavid J Pinato, Takahiro Kaneko, Antonio D'Alessio, et al.
Pageof 24